An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan

ABSTRACT

BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931. More... »

PAGES

84

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3

DOI

http://dx.doi.org/10.1186/s13075-019-1857-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113057001

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30922373


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Metroplex Clinical Research Center", 
          "id": "https://www.grid.ac/institutes/grid.477482.a", 
          "name": [
            "Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Stanley", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario 12 De Octubre", 
          "id": "https://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pablos", 
        "givenName": "Jose L.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Revmatologick\u00fd \u00fastav", 
          "id": "https://www.grid.ac/institutes/grid.418965.7", 
          "name": [
            "Institute of Rheumatology, Prague 2, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavelka", 
        "givenName": "Karel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung.f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u00fcller", 
        "givenName": "Gerard Anton", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Arthritis and Rheumatism Associates", 
          "id": "https://www.grid.ac/institutes/grid.490547.b", 
          "name": [
            "Arthritis and Rheumatism Associates, Wheaton, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kivitz", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hui", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krishnan", 
        "givenName": "Eswar", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/rheumatology/ket260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000218995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.22214", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009901742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012251139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012965699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/1744666x.2015.1090313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013216059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017993092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-209166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023109204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar3147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024364202", 
          "https://doi.org/10.1186/ar3147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032526040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2015.04.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037699729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0049-0172(90)90060-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045775208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078771680", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2016.12.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084083514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-210459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085872012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1106025459", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).\nMETHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40\u2009mg ABP 501 every other week for 68\u2009weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline.\nRESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade\u2009\u2265\u20093 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was -\u20092.25 at the OLE study baseline (n\u2009=\u2009440), -\u20092.36 at week 4 (n\u2009=\u2009463), -\u20092.41 at week 24 (n\u2009=\u2009450), -\u20092.55 at week 48 (n\u2009=\u2009433), and -\u20092.60 at week 70 (n\u2009=\u2009412). Efficacy was maintained throughout the study.\nCONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity.\nTRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-019-1857-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis", 
    "pagination": "84", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-019-1857-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113057001"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30922373"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-019-1857-3", 
      "https://app.dimensions.ai/details/publication/pub.1113057001"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13075-019-1857-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      49 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-019-1857-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N34a10a3f077f48449c1369a9c410cda0
4 schema:citation sg:pub.10.1007/s11926-016-0601-0
5 sg:pub.10.1007/s40259-016-0184-3
6 sg:pub.10.1007/s40259-016-0185-2
7 sg:pub.10.1007/s40259-017-0218-5
8 sg:pub.10.1186/ar3147
9 https://app.dimensions.ai/details/publication/pub.1078771680
10 https://app.dimensions.ai/details/publication/pub.1106025459
11 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w
12 https://doi.org/10.1002/art.22214
13 https://doi.org/10.1016/0049-0172(90)90060-s
14 https://doi.org/10.1016/j.jaad.2016.12.014
15 https://doi.org/10.1016/j.semarthrit.2015.04.002
16 https://doi.org/10.1016/j.semarthrit.2016.01.001
17 https://doi.org/10.1016/j.semarthrit.2016.01.002
18 https://doi.org/10.1093/rheumatology/ker124
19 https://doi.org/10.1093/rheumatology/ket260
20 https://doi.org/10.1111/bjd.15857
21 https://doi.org/10.1136/annrheumdis-2016-209166
22 https://doi.org/10.1136/annrheumdis-2016-210459
23 https://doi.org/10.1586/1744666x.2015.1090313
24 schema:datePublished 2019-12
25 schema:datePublishedReg 2019-12-01
26 schema:description BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N971b2da0e5494e3ead7d94f0d52272be
31 Nc66fa021ae914370ac9223ab5459d3ed
32 sg:journal.1297499
33 schema:name An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
34 schema:pagination 84
35 schema:productId N81671391136f46d980ac8f0a45262762
36 N8afd2f5ec8404dff8cb67a02cf523298
37 Nb894e7567ce04122894e8750b13e10a4
38 Ncf169addbe3f425b87fd7384112652aa
39 Ndf9c17168b8a480ca7562fed1808ceea
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113057001
41 https://doi.org/10.1186/s13075-019-1857-3
42 schema:sdDatePublished 2019-04-16T06:25
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher Nf2eae0fd4b9442e78b672fe386399a52
45 schema:url https://link.springer.com/10.1186%2Fs13075-019-1857-3
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N0d7a0b43571849fc84b749a788ef3a8e schema:affiliation https://www.grid.ac/institutes/grid.417886.4
50 schema:familyName Wang
51 schema:givenName Hui
52 rdf:type schema:Person
53 N137af9e85fe54b3b93f7493f075012bc rdf:first N4983fdb4b69e4f2ea09f30a8c7be3fd2
54 rdf:rest N8d29b864148e4571b1d672b6325f6aa3
55 N2886f09a0a244afead3e45839652a8ec schema:affiliation https://www.grid.ac/institutes/grid.490547.b
56 schema:familyName Matsumoto
57 schema:givenName Alan
58 rdf:type schema:Person
59 N34a10a3f077f48449c1369a9c410cda0 rdf:first N8d2a282aa61f4c50b7f5c6cb34a9ea66
60 rdf:rest N4e849c08638a4a58b28dcb88fadea335
61 N4983fdb4b69e4f2ea09f30a8c7be3fd2 schema:affiliation Nd0dd3f12e7234bf485cd5870e98a660d
62 schema:familyName Kivitz
63 schema:givenName Alan
64 rdf:type schema:Person
65 N4d28ad527af1410f80d0043470d936ee schema:affiliation https://www.grid.ac/institutes/grid.417886.4
66 schema:familyName Krishnan
67 schema:givenName Eswar
68 rdf:type schema:Person
69 N4e849c08638a4a58b28dcb88fadea335 rdf:first Naa39bc09f9474cb9bafc6ff2ede33ff4
70 rdf:rest Nf3d23a38e6bc429c9c2090af63d332f7
71 N4fa57422e9574f1cb4680e852c34040c rdf:first N4d28ad527af1410f80d0043470d936ee
72 rdf:rest rdf:nil
73 N5513b1f3b2b74a0dbaaf1c5764f9b5fd schema:affiliation https://www.grid.ac/institutes/grid.418965.7
74 schema:familyName Pavelka
75 schema:givenName Karel
76 rdf:type schema:Person
77 N60cfea7664cc4f949780845936a8e690 schema:affiliation Ne565af63e21447f384433402b7804267
78 schema:familyName Müller
79 schema:givenName Gerard Anton
80 rdf:type schema:Person
81 N6efab29d413f4e2c81aa11dc21f9d9a2 rdf:first N60cfea7664cc4f949780845936a8e690
82 rdf:rest Nbd42a2847abb4d7486d09f70c23931e1
83 N81671391136f46d980ac8f0a45262762 schema:name nlm_unique_id
84 schema:value 101154438
85 rdf:type schema:PropertyValue
86 N8afd2f5ec8404dff8cb67a02cf523298 schema:name doi
87 schema:value 10.1186/s13075-019-1857-3
88 rdf:type schema:PropertyValue
89 N8d29b864148e4571b1d672b6325f6aa3 rdf:first N0d7a0b43571849fc84b749a788ef3a8e
90 rdf:rest N4fa57422e9574f1cb4680e852c34040c
91 N8d2a282aa61f4c50b7f5c6cb34a9ea66 schema:affiliation https://www.grid.ac/institutes/grid.477482.a
92 schema:familyName Cohen
93 schema:givenName Stanley
94 rdf:type schema:Person
95 N971b2da0e5494e3ead7d94f0d52272be schema:issueNumber 1
96 rdf:type schema:PublicationIssue
97 Naa39bc09f9474cb9bafc6ff2ede33ff4 schema:affiliation https://www.grid.ac/institutes/grid.144756.5
98 schema:familyName Pablos
99 schema:givenName Jose L.
100 rdf:type schema:Person
101 Nb894e7567ce04122894e8750b13e10a4 schema:name readcube_id
102 schema:value 9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38
103 rdf:type schema:PropertyValue
104 Nbd42a2847abb4d7486d09f70c23931e1 rdf:first N2886f09a0a244afead3e45839652a8ec
105 rdf:rest N137af9e85fe54b3b93f7493f075012bc
106 Nc66fa021ae914370ac9223ab5459d3ed schema:volumeNumber 21
107 rdf:type schema:PublicationVolume
108 Ncf169addbe3f425b87fd7384112652aa schema:name pubmed_id
109 schema:value 30922373
110 rdf:type schema:PropertyValue
111 Nd0dd3f12e7234bf485cd5870e98a660d schema:name Abteilung für Nephrologie und Rheumatologie, Göttingen, Germany
112 rdf:type schema:Organization
113 Ndf9c17168b8a480ca7562fed1808ceea schema:name dimensions_id
114 schema:value pub.1113057001
115 rdf:type schema:PropertyValue
116 Ne565af63e21447f384433402b7804267 schema:name Abteilung.für Nephrologie und Rheumatologie, Göttingen, Germany
117 rdf:type schema:Organization
118 Nf2eae0fd4b9442e78b672fe386399a52 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Nf3d23a38e6bc429c9c2090af63d332f7 rdf:first N5513b1f3b2b74a0dbaaf1c5764f9b5fd
121 rdf:rest N6efab29d413f4e2c81aa11dc21f9d9a2
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
126 schema:name Clinical Sciences
127 rdf:type schema:DefinedTerm
128 sg:journal.1297499 schema:issn 1478-6354
129 1478-6362
130 schema:name Arthritis Research & Therapy
131 rdf:type schema:Periodical
132 sg:pub.10.1007/s11926-016-0601-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040002812
133 https://doi.org/10.1007/s11926-016-0601-0
134 rdf:type schema:CreativeWork
135 sg:pub.10.1007/s40259-016-0184-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038300105
136 https://doi.org/10.1007/s40259-016-0184-3
137 rdf:type schema:CreativeWork
138 sg:pub.10.1007/s40259-016-0185-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042463549
139 https://doi.org/10.1007/s40259-016-0185-2
140 rdf:type schema:CreativeWork
141 sg:pub.10.1007/s40259-017-0218-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085050557
142 https://doi.org/10.1007/s40259-017-0218-5
143 rdf:type schema:CreativeWork
144 sg:pub.10.1186/ar3147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024364202
145 https://doi.org/10.1186/ar3147
146 rdf:type schema:CreativeWork
147 https://app.dimensions.ai/details/publication/pub.1078771680 schema:CreativeWork
148 https://app.dimensions.ai/details/publication/pub.1106025459 schema:CreativeWork
149 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1017993092
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1002/art.22214 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009901742
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1016/0049-0172(90)90060-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1045775208
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1016/j.jaad.2016.12.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084083514
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1016/j.semarthrit.2015.04.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037699729
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/j.semarthrit.2016.01.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032526040
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/j.semarthrit.2016.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012251139
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1093/rheumatology/ker124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012965699
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1093/rheumatology/ket260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000218995
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1111/bjd.15857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090920617
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1136/annrheumdis-2016-209166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023109204
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1136/annrheumdis-2016-210459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085872012
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1586/1744666x.2015.1090313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013216059
174 rdf:type schema:CreativeWork
175 https://www.grid.ac/institutes/grid.144756.5 schema:alternateName Hospital Universitario 12 De Octubre
176 schema:name Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
177 rdf:type schema:Organization
178 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
179 schema:name Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA
180 rdf:type schema:Organization
181 https://www.grid.ac/institutes/grid.418965.7 schema:alternateName Revmatologický ústav
182 schema:name Institute of Rheumatology, Prague 2, Czech Republic
183 rdf:type schema:Organization
184 https://www.grid.ac/institutes/grid.477482.a schema:alternateName Metroplex Clinical Research Center
185 schema:name Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.490547.b schema:alternateName Arthritis and Rheumatism Associates
188 schema:name Arthritis and Rheumatism Associates, Wheaton, MD, USA
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...